Editing Ciprofloxacin (section)

===Children===
Oral and intravenous ciprofloxacin are approved by the FDA for use in children for only two indications due to the risk of permanent injury to the musculoskeletal system:
# Inhalational [[anthrax]] (postexposure)<ref>{{cite web |url=http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2000/20780S08ltr.pdf |title=Cipro Labeling Revision Letter 08/30/2000 Supplement 008 New or Modified Indication |vauthors = Murphy D |publisher=U.S. [[Food and Drug Administration]] |date=30 August 2000 |url-status=live |archive-url=https://web.archive.org/web/20121018202604/http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2000/20780S08ltr.pdf |archive-date=18 October 2012}}</ref>
# Complicated urinary tract infections and [[pyelonephritis]] due to ''Escherichia coli'',<ref name=cipro2004>{{cite web |vauthors = Albrecht R |title=Cipro Labeling Revision Letter 03/25/2004 Supplement 049 Patient Population Altered |url=http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2004/19537s049,19857s031,19847s027,20780s013ltr.pdf |publisher=U.S. [[Food and Drug Administration]] |date=25 March 2004 |access-date=7 September 2009 |url-status=live |archive-url=https://web.archive.org/web/20121018202556/http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2004/19537s049,19857s031,19847s027,20780s013ltr.pdf |archive-date=18 October 2012}}</ref> but never as first-line agents.